AstraZeneca PLC Third Quarter & Nine Months Results 2009, Astra Zeneca
Release Date: 2009-10-29
Strong business performance has been driven by good operating execution bolstered by revenue upsides from Toprol-XL and H1N1 vaccine sales. Core EPS target for the year has been increased and progress has been made on the pipeline with the approval of ONGLYZATM, the European submission for Brilinta and new external collaborations, tempered by the disappointing news on Zactima.| Type: | NORMAL |
| Company: | Astra Zeneca |
| Country: | Italy |